Asploro Journal of Biomedical and Clinical Case Reports

ISSN: 2582-0370
Article Type: Case Report
DOI: 10.36502/2023/ASJBCCR.6284
Asp Biomed Clin Case Rep. 2023 Feb 04;6(1):17-22
Masaki OKADA1, Hiroshi BANDO1,2iD*, Noboru IWATSUKI1, Kazuki SAKAMOTO1, Tomoya OGAWA1
1Sakamoto Hospital, Higashi Kagawa city, Kagawa, Japan
2Tokushima University/Medical research, Tokushima, Japan
Corresponding Author: Hiroshi BANDO, MD, PhD, FACP ORCID iD
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 23 January 2023; Accepted date: 31 January 2023; Published date: 04 February 2023
Citation: Okada M, Bando H, Iwatsuki N, Sakamoto K, Ogawa T. Elderly Female of Type 2 Diabetes (T2D) and Dementia with Clinical Improvement by Imeglimin (Twymeeg). Asp Biomed Clin Case Rep. 2023 Feb 04;6(1):17-22.
Copyright © 2023 Okada M, Bando H, Iwatsuki N, Sakamoto K, Ogawa T. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
Keywords: Imeglimin (Twymeeg), Type 2 Diabetes, Zinc Acetate Hydrate, Novelzin, Trials of IMeglimin for Efficacy and Safety, Neuropsychiatric Symptoms in Dementia, Alzheimer’s-Plus with Low Zinc
Abbreviations: T2D: Type 2 Diabetes; Novelzin: Zinc Acetate Hydrate; TIMES: Trials of IMeglimin for Efficacy and Safety; APLZ: Alzheimer’s-Plus with Low Zinc
Abstract
Background: Recent diabetic focus includes imeglimin (Twymeeg).
Case Presentation: The case was an 83-year-old female with 19 years of type 2 diabetes (T2D) associated with recent treatment for dementia.
Result: HbA1c decreased from 10.0% to 6.6% for 4 months by Twymeeg 2000 mg/day. For neuropsychiatric symptoms in dementia, memantine and tiapride were provided and controlled. Furthermore, zinc acetate hydrate (Novelzin) was continued for T2D and dementia.
Discussion and Conclusion: Twymeeg administration was effective as the results of Trials of IMeglimin for Efficacy and Safety (TIMES) 2 and 3. Perspectives on the efficacy of zinc were discussed including Alzheimer’s-Plus with low zinc (APLZ).






